PRODUCTION OF HUMAN ANTIMALARIAL CRISIS FORM FACTOR

疟疾，由于恶性疟原虫，仍然是最重要的人类 世界上最大的传染病。过去的控制措施一直是 不足以限制疾病的发病率和后果。 目前，大量的关注和资金正被引导到 寻找一种抗疟疾疫苗。这些程序支持搜索 寄生虫抗原可通过以下途径刺激人类保护性免疫 抗体依赖机制。然而，获得性保护性免疫 对生活在疟疾地区的人类中发现的疟疾的了解很少。 仅仅基于抗体的疫苗是可能的，如果不是很可能的话。 在控制疟疾方面的作用相对有限。Jensen等人报道 强有力的证据表明，中国人对恶性疟疾自然产生了免疫力 苏丹涉及细胞介导的免疫反应的主要贡献。 在体外，苏丹免疫血清导致严重的迟缓 恶性疟原虫的红细胞内发育导致其出现 形态上典型的“危机形式”。我们把这个因素命名为 负责活动危机形成因素(CFF)。从长远来看 这项研究的目标是能够生产CFF用作 在疟疾的临床管理中可能的治疗剂，或 刺激体内保护性物质的产生作为一种潜在的手段 关于预防的。这两种方法都需要提纯、表征 以及来自人免疫血清来源的CFF的特异性定量。这个 第一阶段可行性研究的具体目标是开发免疫分析 程序基于生产抗CFF的单抗。

Malaria, due to Plasmodium falciparum remains the most important human infectious disease in the world. Past control measures have been inadequate to limit the incidence and consequences of the disease. Currently, a great deal of attention and funding is being directed to the search for an antimalarial vaccine. These programs support the search for parasite antigens which could stimulate protective immunity in humans via antibody-dependent mechanisms. However, the acquired protective immunity to malaria found in humans living in malarious areas is poorly understood. It is possible, if not likely, that vaccines based on antibody alone will be of relatively limited use in controlling malaria. Jensen et al reported strong evidence that naturally acquired immunity to falciparum malaria in Sudan involves a major contribution from cell-mediated immune responses. In vitro, Sudanese immune sera cause a profound retardation in the intraerythrocytic development of P. falciparum resulting in the appearance of morphologically typical "crisis forms." We have termed the factor responsible for the activity crisis-form factor (CFF). The long term objectives of this research are to be able to produce CFF for use as a possible therapeutic agent in the clinical management of malaria, or to stimulate production of protective substance in vivo as a potential means of prophylaxis. Both approaches require the purification, characterization and specific quantitation of CFF from human immune serum sources. The specific aim of the Phase 1 feasibility study is to develop immunoassay procedures based on the production of anti-CFF monoclonal antibodies.